Diagnostic Tests and Patent Eligibility: Will the Federal Circuit's Negative Treatment Chill Innovation?

In PerkinElmer, Inc. v. Intema, Ltd., the Court of Appeals for the Federal Circuit (CAFC) revisits the subject of patent eligibility as it relates to diagnostic methods and invalidates the claims of a diagnostic test for Down's syndrome as being patent-ineligible, This decision is significant a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Genetic engineering & biotechnology news 2013-03, Vol.33 (5), p.8-8
1. Verfasser:	Belliveau, Michael J
Format:	Magazinearticle
Sprache:	eng
Schlagworte:	Appeals Biotechnology Circuits Dangerous Diagnostic systems Evolution Genetic engineering
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!